Currently, there is no available medical device or standard of treatment on the market for the repair of advanced joint injury in adults between ages 18 to 55. Such injuries are generally the result of sports injury, accidents, or congenital defects that have been left untreated. In each case, treatment is difficult because injuries are often sizeable, painful, cannot self-heal, and impact patient mobility. Furthermore, young and active patients require surgical solutions that will heal fast and return them to a full level of activity and quality of life.

Nanochon is applying novel materials to replicate bone and cartilage, and high-end 3-D printing to create an implant which can permanently repair debilitating joint injuries. The Nanochon implant can bear loads like a traditional joint implant, quickly restoring a patient’s movement. Over time, however, damaged joint tissue grows into the implant, fusing with the implant’s material and creating a long lasting bond, eventually leaving behind a fully healed joint.

The Nanochon implant acts as both cartilage replacement and tissue growth scaffold, and is designed to be custom 3-D printed for each patient. The marriage of technology to produce better patient outcomes with a hospital’s device demands more flexibly leads to overall more effective treatment and recovery. Nanochon provides an easy-to-use surgical implant that can quickly return younger patients to a full quality of life. Testing of a manufactured prototype in a large animal patient has been completed, demonstrating clinical and therapeutic benefits of the device. The goal now is to secure funding scale up manufacturing of the device and complete a human trial in 2019-2020. The device will be a candidate for the Premarket Approval (PMA) regulatory pathway in the US.